Following the FDA ODD, European designation underscores ICT01’s potential as a novel immunotherapy approach in AML ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ICT01 selectively activates circulating γ9δ2 T cells that leads to migration of γ9δ2 T cells out of the circulation and into target tissue (e.g., tumors or infection site), ...

ImCheck Therapeutics SAS. ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022. Continued positive safety data across a ...

Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trial show strong safety profile and encouraging clinical activity for ICT01 monotherapy in relapsed/refractory ...

ImCheck Reports High Remission Rates in AML Patientswith ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission ...

Two clinical trials are underway to test ICT01: Eviction is testing the drug alone and in combination with Merck's Keytruda. Eviction-2 is testing the drug with an IL-2 inhibitor.

ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023Interim data from ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023 Interim data from Phase I dose escalation portion of EVICTION Phase I/IIa trialshow strong safety ...